Loading
A phase 2 trial of Savolitinib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC is a phase 2 interventional study registered as NCT05374603 by AstraZeneca, with 47 participants enrolled, started 2022-11-15 and due to reach its primary completion in 2027-01-18. Interventions recorded: Savolitinib and Durvalumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/